InnDura Therapeutics is a biotechnology company developing next-generation in vivo immune-cell engineering therapies for autoimmune diseases and cancer. Its proprietary EVE16 platform enables precise, cell-restricted activation of T cells, NK cells, and monocytes by leveraging native immune signaling pathways. InnDura delivers EVE16 as mRNA encapsulated in targeted lipid nanoparticles, enabling scalable, off-the-shelf in vivo immune engineering with enhanced potency and safety relative to CAR-based approaches. The company is building a pipeline of autoimmune and oncology programs and is pursuing strategic partnerships and out-licensing opportunities.